Table 2.

Composition of the observed experience by age category among persons initiating ESRD care from 1995 to 2013 in the United States

VariableAge Category, yr
0–1415–2425–4445–64≥65
Person-years of observation
 Overall observation55,467153,3161,170,4903,010,6352,574,543
 During treatment with dialysis19,67182,286780,4082,300,0202,328,056
 During time with a functioning transplant35,79671,030390,532710,615246,487
Age at first ESRD service, yr5 [2–10]18 [15–21]34 [28–38]53 [47–58]70 [66–76]
 Missing, %00000
Males, %6056585853
 Missing00000
Race, %
 White7263545767
 Black1827383526
 Other1110887
 Missing00000
Primary kidney disease, %
 Diabetes<12254545
 Hypertension18222230
 GNa234330149
 Congenital anomalies of the kidneys and urinary tract391831<1
 Others3226181816
 Missing54111
Socioeconomic quartile, %
 Lowest1821242521
 Midlow1618191919
 Midhigh2323242324
 Highest3330282832
 Missing98554
Primary insurance coverage, %
 Medicare/Medicaid5340353976
 Employer/other4042424516
 No coverage41420133
 Missing45435
Comorbidities,b %
 None9289603625
 169283331
 2–322112534
 ≥4<1<11610
Deaths, n
 Overall observation1151336563,123358,485838,668
 During treatment with dialysis947304859,601340,804822,966
 During treatment with transplant204317352217,68115,702
Observed absolute mortality rate per 1000 person-years (95% CI)
 Over all observation20.8 (12.5 to 29.0)21.9 (17.0 to 26.9)53.9 (52.2 to 55.7)119.1 (118.0 to 120.1)325.8 (324.8 to 326.8)
 During treatment with dialysis48.1 (34.5 to 61.8)37.0 (30.3 to 43.7)76.4 (74.2 to 78.5)148.2 (147.0 to 149.4)353.5 (352.5 to 354.5)
 During treatment with transplant5.7 (4.6 to 16.0)4.5 (2.9 to 11.8)9.0 (5.9 to 12.1)24.9 (22.6 to 27.2)63.7 (59.9 to 67.5)
  • Because the unit of analysis was person-time rather than person, the characteristics presented are weighted by a factor derived from the number of person-years of observation and number of events and presented as weighted median [interquartile range] or percentage (for example, percentage of person-years contributed by men). 95% CI, 95% confidence interval.

  • a Includes FSGS.

  • b Comorbidities counted included congestive heart failure, ischemic heart disease/coronary artery disease, myocardial infarction, cardiac arrest, cardiac dysrhythmia, pericarditis, atherosclerotic heart disease, other cardiac disease, cerebrovascular disease/cerebrovascular accident/transient ischemic attack, peripheral vascular disease, diabetes, chronic obstructive pulmonary disease, current tobacco use, malignancy, alcohol dependence, drug dependence, inability to ambulate, and inability to transfer. If no comorbidities were reported, it was assumed that there were none.